儿童硬化性胆管炎预后指数(SCOPE):一种儿童预后工具
基于儿童原发性硬化性胆管炎(PSC) consortium 的回顾性数据,用 1,012 例患者(40 个中心)建立包含总胆红素、白蛋白、血小板计数、γ-谷氨酰转移酶和胆管造影的多变量风险指数(SCOPE),将患者分为低、中、高危,预测肝移植或死亡及肝胆并发症,并在 240 例(11 个中心)中验证。
要点
- SCOPE 指数基于总胆红素、白蛋白、血小板计数、γ-谷氨酰转移酶和胆管造影,预测儿童 PSC 的肝移植或死亡及肝胆并发症。
- 低、中、高危组进展至肝移植或死亡的年率分别为 <1%、3%、9%,至肝胆并发症的年率分别为 2%、6%、13%(P < 0.001)。
- SCOPE 与活检证实的肝纤维化相关,可用于临床共同决策和未来临床试验设计。
核心结论
- SCOPE 指数是儿童 PSC 的特异性预后工具,使用常规客观数据预测复杂临床病程,并与活检证实的肝纤维化强相关。
研究设计与样本
- 研究为回顾性研究,使用儿童 PSC consortium 的数据;训练队列包含来自 40 个中心的 1,012 例患者,验证队列包含来自 11 个额外中心的 240 例儿童。
主要发现
- 模型将患者分为低、中、高危,进展至肝移植或死亡的年率分别为 <1%、3%、9%,进展至肝胆并发症的年率分别为 2%、6%、13%(P < 0.001)。
- 1 年和 5 年区分肝移植或死亡的 C 统计量分别为 0.95 和 0.82,区分肝胆并发症的 C 统计量分别为 0.80 和 0.76。
- 基线肝纤维化分期随风险评分增加而更差,最低风险指数组广泛纤维化为 8%,最高风险指数组为 100%(P < 0.001)。
- 模型在 240 例儿童中验证表现良好。
临床怎么用
- SCOPE 可用于与家庭基于患者个体风险进行临床照护的共同决策,并在设计未来临床试验时考虑疾病进展的变异性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Disease progression in children with primary sclerosing cholangitis (PSC) is variable. Prognostic and risk-stratification tools exist for adult-onset PSC, but not for children. We aimed to create a tool that accounts for the biochemical and phenotypic features and early disease stage of pediatric PSC. APPROACH AND RESULTS: We used retrospective data from the Pediatric PSC Consortium. The training cohort contained 1,012 patients from 40 centers. We generated a multivariate risk index (Sclerosing Cholangitis Outcomes in Pediatrics [SCOPE] index) that contained total bilirubin, albumin, platelet count, gamma glutamyltransferase, and cholangiography to predict a primary outcome of liver transplantation or death (TD) and a broader secondary outcome that included portal hypertensive, biliary, and cancer complications termed hepatobiliary complications (HBCs). The model stratified patients as low, medium, or high risk based on progression to TD at rates of <1%, 3%, and 9% annually and to HBCs at rates of 2%, 6%, and 13% annually, respectively (P < 0.001). C-statistics to discriminate outcomes at 1 and 5 years were 0.95 and 0.82 for TD and 0.80 and 0.76 for HBCs, respectively. Baseline hepatic fibrosis stage was worse with increasing risk score, with extensive fibrosis in 8% of the lowest versus 100% with the highest risk index (P < 0.001). The model was validated in 240 children from 11 additional centers and performed well. CONCLUSIONS: The SCOPE index is a pediatric-specific prognostic tool for PSC. It uses routinely obtained, objective data to predict a complicated clinical course. It correlates strongly with biopsy-proven liver fibrosis. SCOPE can be used with families for shared decision making on clinical care based on a patient's individual risk, and to account for variable disease progression when designing future clinical trials.
引用
- Deneau MR, Mack C, Perito ER, et al. The Sclerosing Cholangitis Outcomes in Pediatrics (SCOPE) Index: A Prognostic Tool for Children. Hepatology. 2020. PMID: 32464706. doi:10.1002/hep.31393
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。